Romatoloji Pratiğinde İnterstitiel Akciğer Hastalığı: Tek Merkez Deneyimi

Year 2017, Volume: 3 Issue: 2, 71 - 82, 01.01.2017

Funda Erbasan Şuayp Oygen Edip Gökalp Gök Gökhan Tazegül Mustafa Ender Terzioğlu Veli Yazısız

Abstract

Amaç: İnterstitiel akciğer hastalığı İAH akciğerlerdeki interstitiel aralığı etkileyen heterojen bir hastalık grubudur. İAH bağ doku hastalıklarına BDH sekonder gelişebilir ve solunum yetmezliğinden dolayı sakatlık ve ölüm oranı artar. Bu çalışmanın amacı BDH ilişkili İAH'nın klinik, laboratuvar ve görüntüleme özelliklerini tanımlamak ve tedavi yaklaşımlarını analiz etmektir. Gereç ve Yöntemler: Bu çalışmaya ardışık gelen 132 İAH hastası alındı. Demografik özellikleri, laboratuvar ve yüksek rezolüsyonlu akciğer tomografisi HRCT ve tedavi sonuçları analiz edildi. bulgular: BDH ilişkili İAH tanısı alan 99 hasta vardı. Ortalama yaş 54.7±11.6 yıl, kadın oranı %82.8, median takip süresi 48.5 aydı. 96 hastanın takip süresi altı aydan fazlaydı. HRCT taramaları median 12.5 aylık intervaller ile median 3 kez tekrarlanmıştı. En sık HRCT bulguları buzlu cam opasiteleri ve interlobüler septal kalınlaşmalardır. Hastaların üçte birinde bal peteği paterni vardı. Hastaların %89.6'sı kortikosteroid %44.8'i antimalaryal ajan almıştı. Azatiopürin ve siklofosfamid en sık kullanılan immünosupresif ilaçlardı. Tedavi sonrası ortalama solunum fonksiyon testleri tedavi monoxide DLCO are used for monitorization. Reduced FVC levels show advanced disease and more than 10% decrease is related with poor prognosis 19 . HRCT also correlates with spirometric measurements and may be used in follow-up 20 . Connective tissue diseases are a principal group of rheumatologic diseases and they constitute an important part of rheumatological practice. Pulmonary symptoms of these patients require a good differential diagnosis and treatment approach. Although there are a number of recent studies focusing on CTD-ILDs, there is no consensus on the diagnosis, follow-up and treatment of these patients. In this study, we aim to present a single rheumatology center clinical experience of patients with ILD. Furthermore, we reported the clinical, laboratory, imaging results and treatment approaches of patients with CTD-ILD.MAtErIAL and MEtHODSStudy populationöncesinden farklı değildi p>0.05 . Tedavi ile hastaların %35'inde zorlu vital kapasite düzelmiş FVC >%10 artış , %31'inde azalmış ve %34'ünde değişmemişti. Sonuç: BDH ilişkili İAH tanı, tedavi ve takibi için yoğun çaba harcanmasına rağmen tedavide henüz tatmin edici noktaya ulaşılmamıştır. BDH ilişkili İAH hastaları için yeni kür sağlayıcı ajanlara ihtiyaç vardır

Keywords

Bağ doku hastalıkları, İnterstitiel akciğer hastalığı, Yüksek rezolusyonlu akciğer tomografisi

Interstitial Lung Diseases in Rheumatology Practice: A Single Center Experience

Abstract

Objective: Interstitial lung diseases ILDs are a heterogeneous group of pulmonary diseases affecting the pulmonary interstitium. ILDs may occur secondary to connective tissue diseases CTDs and increase morbidity and mortality due to ventilation impairment. The aim of this study was to reveal the clinical, laboratory and imaging features of CTD-related ILDs CTD-ILDs and to analyze the treatment approaches.Material and Methods: A total of 132 consecutive ILD patients were included in this cohort. Demographic characteristics, laboratory and high-resolution chest computed tomography HRCT results and treatments were analyzed.results: There were 99 patients with CTD-ILD, the mean age was 54.7±11.6 years, females made up 82.8%, median follow-up time was 48.5 months. There were 96 patients who were followed up for more than six months. The median number of HRCT scans was 3 with a median interval of 12.5 months. Most common HRCT findings were ground-glass opacities and interlobular septal thickening. One-third of all scans had a honeycomb pattern. 89.6% of CTD-ILD patients recieved corticosteroids, and 44.8% recieved antimalarials. Azathioprine and cyclophosphamide were the most commonly used immunosuppressive drugs. After treatment, the mean pulmonary function tests did not significantly differ from the baseline p >0.05 . 35% of the patients had improved forced vital capacity FVC >10% increase with treatment whereas 31% had decreased values and 34% were stable. conclusion: The desired point of the treatment of CTD-ILD patients has not been reached yet even though a significant effort is being made for the diagnosis, treatment and follow up. Novel curative agents are needed for patients with CTD-ILD

Keywords

Connective tissue diseases, High-resolution computed tomography, Interstitial lung diseases

References

• Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012;380 (9842):689-98.
• Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, Wallace WA, Wells AU, Whyte MK, Wilsher ML; British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008; Suppl 5:v1-58.
• Ruano CA, Lucas RN, Leal CI, Lourenço J, Pinheiro S, Fernandes O,Ruano CA, Lucas RN, Leal CI, Lourenço J, Pinheiro S, Fernandes O, Figueiredo L. Thoracic manifestations of connective tissue diseases. Curr Probl Diagn Radiol 2015;44(1):47-59.
• Wang JX, Du CG. A retrospective study of clinical characteristics of interstitial lung disease associated with rheumatoid arthritis in Chinese patients. Med Sci Monit 2015; 21:708-15.
• Palm O, Garen T, Berge Enger T, Jensen JL, Lund MB, Aalokken TM, Gran TJ. Clinical pulmonary involvement in primary Sjogren’s syndrome: Prevalence, quality of life and mortality-a retrospective study based on registry data. Rheumatology (Oxford) 2013;52(1):173-9.
• Yazisiz V, Arslan G, Ozbudak IH, Türker S, Erbasan F, Avci AB, Ozbudak O, Terzioğlu E. Lung involvement in patients with primary Sjögren’s syndrome: What are the predictors? Rheumatol Int 2010;30(10):1317-24.
• Bertoli AM, Vila LM, Apte M, Fessler BJ, Bastian HM, Reveille JD, Alarcon GS. LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: Factors predictive of pulmonary damage. Lupus 2007;16(6):410-7.
• Jain S, Shahane A, Derk CT. Interstitial lung disease in systemic sclerosis: Patho-physiology, current and new advances in therapy. Inflamm Allergy Drug Targets 2012;11(4): 266-77.
• Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, Murpy J, Cohen M, Raghu G, Brown KK. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011;183:372–8.
• Komocsi A, Vorobcsuk A, Faludi R, Pintér T, Lenkey Z, Költo G, Crizjak L. The impact of cardiopulmonary manifestations on the mortality of SSc: A systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2012;51:1027-36.
• Saketkoo LA, Matteson EL, Brown KK, Seibold JR, Strand V. Developing disease activity and response criteria in connective tissue disease related interstitial lung disease. J Rheumatol 2011;38(7):1514-8.
• Wells AU, Denton CP. Interstitial lung disease in connective tissue disease-mechanisms and management. Nat Rev Rheumatol 2014;10(12):728-39.
• American Thoracic Society/European Respiratory and Society. International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonia. Am J Respir Crit Care Med 2002;165: 277-304.
• Assayag D, Elicker BM, Urbania TH, Colby TV, Kang BH, Ryu JH, King TE, Collard HR, Kim DS, Lee LS. Rheumatoid arthritis-associated interstitial lung disease: Radiologic identification of usual interstitial pneumonia pattern. Radiology 2014; 270(2):583-8.
• Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354: 2655-66.
• Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM. A multicenter, prospective, controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54(12):3962-70. double-blind, placebo
• Pathologic and radiologic differences between idiopathic
• and collagen vascular disease-related usual interstitial
• Launay D, Le Guern V, Kahn JE, Couderc LJ, Constans J, Cohen P, Mahr A, Pagnoux C, Hachulla E, Kahan A, Cabane J, Guillevin L, Mouthon L. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: A retrospective multicenter open-label study. J Rheumatol 2008;35: 1064–72.
• Gonzalez-Nieto JA, Martin-Suarez IJ, Gil-Muñoz FL. Efficacy of mycophenolate associated with methotrexate as a maintenance treatment for systemic sclerosis associated interstitial lung disease. Arch Bronconeumol 2011;47(11): 575.
• Tochimoto A, Kawaguchi Y, Hara M, Tataishi M, Fucasawa C, Tagaki K, Nishimagi E, Ota Y, Katsumata Y, Gono T, Tanaka E, Yamanaka H. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Mod Rheumatol 2011;21:296-301.
• White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132(12): 947-54.
• Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L, Scorza R. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: Experience in one centre. Clin Rheumatol 2007;26(2): 168-72.
• Airò P, Danieli E, Rossi M, Frassi M, Cavazzana I, Scarsi M, Grottolo A, Franceschini F, Zambruni A. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: Results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 2007;25(2): 293-6.
• Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002;29(2): 298-304.
• Vlachoyiannopoulos PG.
• Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low- dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 2013;20(5).838-44.
• Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, Fulminis A, De Luca A, Farina G, Candela M, Generini S, De Francisci A, Tirri E, Proietti M, Bom- bardieri S, Gabrielli A, Tonietti G, Cerinic MM. Cyclo- phosphamide pulse regimen in. The treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;29(4):731-6.
• Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: A pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002;29(11):2371-8.
• Mittoo S, Wigley FM, Wise R, Xiao H, Hummers L. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. Arthritis Rheum 2007;56(12):4195-202.
• Domiciano DS, Bonfá E, Borges CT, Kairalla RA, Capelozzi VL, Parra E, Christmann RB. A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clin Rheumatol 2011;30 (2): 223-9.
• Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, et al.Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: A long term study. Open Respir Med J 2008;2: 39-45.
• Yiannopoulos G, Pastromas V, Antonopoulos I, Katsiberis G, Kalliolias G, Liossis SN, Andonopoulos AP. Combination of intravenous pulses of cyclophosphamide and methylprednisolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 2007;27(4): 357-61.
• Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994;37: 729-35.
• Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008;133:455-60.
• Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010;29:1167-8.
• Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE Jr, Golden JA. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008;102:150-5.
• Yilmaz N, Can M, Kocakaya D, Karakurt S, Yavuz S. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: A case series. Int J Rheum Dis 2014;17(8):923-8.
• Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, Huie TJ, Krishnamoorthy M, Meehan RT, Olson AL, Solomon JJ, Swigris JJ. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013;40:640-6.
• Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells AU, Renzoni EA. Rituximab in severe, treatment- refractory interstitial lung disease. Respirology 2014;19:353-9.
• Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: A meta-analysis of randomized controlled trials. Arthritis Rheumatol 2014; 66(4):803-12.
• van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72.
• Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.